Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Judith Hartleib‐Geschwindner"'
Autor:
Iain B. Squire, Anders Gabrielsen, Peter J. Greasley, Linda Wernevik, Judith Hartleib‐Geschwindner, Julie Holden, Susanne Johansson, Anna Rudvik, José Sánchez, Krister Bamberg, Johanna Melin, Andrew Whittaker
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 10, Pp 2493-2504 (2022)
Abstract This phase Ib study compared the effects of AZD9977, a selective mineralocorticoid receptor modulator with predicted low hyperkalemia risk, with spironolactone on serum potassium (sK+) in patients with heart failure (HF) with preserved or mi
Externí odkaz:
https://doaj.org/article/2c5d085dcf634af18af1d476fc6a3cbd
Autor:
Roberto Palacios-Ramirez, Ixchel Lima-Posada, Benjamin Bonnard, Marie Genty, Amaya Fernandez-Celis, Judith Hartleib-Geschwindner, Fabienne Foufelle, Natalia Lopez-Andres, Krister Bamberg, Frederic Jaisser
Publikováno v:
Frontiers in Physiology, Vol 13 (2022)
Obesity and/or metabolic diseases are frequently associated with chronic kidney disease and several factors associated with obesity may contribute to proteinuria and extracellular matrix production. Mineralocorticoid receptor antagonists have proven
Externí odkaz:
https://doaj.org/article/a49651276bb74066ac4def4c46464815
Autor:
Krister Bamberg, Lena William-Olsson, Ulrika Johansson, Anders Arner, Judith Hartleib-Geschwindner, Johan Sällström
Publikováno v:
Upsala Journal of Medical Sciences, Vol 125, Iss 4, Pp 274-280 (2020)
Background The most profound effect of vasopressin on the kidney is to increase water reabsorption through V2-receptor (V2R) stimulation, but there are also data suggesting effects on calcium transport. To address this issue, we have established an i
Externí odkaz:
https://doaj.org/article/8b68afb4033f4287a8445a134e515857
Autor:
Andrew Whittaker, Åsa M. Kragh, Judith Hartleib‐Geschwindner, Muna Albayaty, Anna Backlund, Peter J. Greasley, Maria Heijer, Magnus Kjaer, Pablo Forte, Robert Unwin, Linda Wernevik, Hans Ericsson
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 2, Pp 275-283 (2020)
Excessive activation of the mineralocorticoid receptor (MR) underlies the pathophysiology of heart failure and chronic kidney disease. Hyperkalemia risk limits the therapeutic use of conventional MR antagonists. AZD9977 is a nonsteroidal, selective M
Externí odkaz:
https://doaj.org/article/abbe228f9fec463ba026031576eb8346
Autor:
Krister Bamberg, Ulrika Johansson, Karl Edman, Lena William-Olsson, Susanna Myhre, Anders Gunnarsson, Stefan Geschwindner, Anna Aagaard, Anna Björnson Granqvist, Frédéric Jaisser, Yufeng Huang, Kenneth L Granberg, Rasmus Jansson-Löfmark, Judith Hartleib-Geschwindner
Publikováno v:
PLoS ONE, Vol 13, Iss 2, p e0193380 (2018)
Excess mineralocorticoid receptor (MR) activation promotes target organ dysfunction, vascular injury and fibrosis. MR antagonists like eplerenone are used for treating heart failure, but their use is limited due to the compound class-inherent hyperka
Externí odkaz:
https://doaj.org/article/837696cf2e364f56bb14da55aad00b11
Autor:
Peter J. Greasley, Pamela J. Hicks, Michael D. Gautreaux, Magnus Althage, Iain MacPhee, Lijun Ma, Tasso Miliotis, Barry I. Freedman, Nicholette D. Palmer, Anna Bogstedt, Timothy M. Heinrich, Judith Hartleib-Geschwindner
Publikováno v:
J Am Soc Nephrol
Autor:
Ulrika Johansson, Lena William-Olsson, Anders Arner, Judith Hartleib-Geschwindner, Krister Bamberg, Johan Sällström
Publikováno v:
Upsala Journal of Medical Sciences
article-version (VoR) Version of Record
Upsala Journal of Medical Sciences, Vol 125, Iss 4, Pp 274-280 (2020)
article-version (VoR) Version of Record
Upsala Journal of Medical Sciences, Vol 125, Iss 4, Pp 274-280 (2020)
Background The most profound effect of vasopressin on the kidney is to increase water reabsorption through V2-receptor (V2R) stimulation, but there are also data suggesting effects on calcium transport. To address this issue, we have established an i
Autor:
M Kjaer, Peter J. Greasley, Maria Heijer, Judith Hartleib-Geschwindner, Muna Albayaty, Pablo Forte, Andrew Whittaker, Robert J. Unwin, Åsa M. Kragh, Anna Backlund, Hans Ericsson, Linda Wernevik
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 2, Pp 275-283 (2020)
Clinical and Translational Science
Clinical and Translational Science
Excessive activation of the mineralocorticoid receptor (MR) underlies the pathophysiology of heart failure and chronic kidney disease. Hyperkalemia risk limits the therapeutic use of conventional MR antagonists. AZD9977 is a nonsteroidal, selective M
Autor:
Kenneth L. Granberg, Zhong-Qing Yuan, Bo Lindmark, Karl Edman, Johan Kajanus, Anders Hogner, Marcus Malmgren, Gavin O’Mahony, Anneli Nordqvist, Jan Lindberg, Stefan Tångefjord, Michael Kossenjans, Christian Löfberg, Jonas Brånalt, Dongmei Liu, Nidhal Selmi, Grigorios Nikitidis, Peter Nordberg, Ahlke Hayen, Anna Aagaard, Eva Hansson, Majlis Hermansson, Ida Ivarsson, Rasmus Jansson-Löfmark, Ulla Karlsson, Ulrika Johansson, Lena William-Olsson, Judith Hartleib-Geschwindner, Krister Bamberg
Publikováno v:
Journal of Medicinal Chemistry. 62:1385-1406
The mechanism-based risk for hyperkalemia has limited the use of mineralocorticoid receptor antagonists (MRAs) like eplerenone in cardio-renal diseases. Here, we describe the structure and property-driven lead generation and optimization, which resul
Autor:
M Kjaer, Krister Bamberg, Hans Ericsson, Linda Wernevik, Judith Hartleib-Geschwindner, Karin Nelander, Fredrik Erlandsson, Rasmus Jansson-Löfmark, Muna Albayaty, Carl Amilon, Ligia Chialda
Publikováno v:
British Journal of Clinical Pharmacology. 84:1486-1493
Aims AZD9977 is the first mineralocorticoid receptor modulator in clinical development exerting similar organ protection as eplerenone with minimal urinary electrolyte effects in preclinical studies. The aim was to perform the initial clinical assess